Organ-on-a-chip Market Research Report - Global Forecast till 2027

Global Organ-on-a-chip Market Research Report: By Organ Type (Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, Human-on-Chip), By Application (Drug Discovery, Toxicology Research, Others) and By End-User (Pharmaceutical Companies, Research Organizations, Others) – Forecast to 2027

ID: MRFR/HC/7026-HCR | February 2021 | Region: Global | 120 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data.

Market Synopsis


Organ-On-a-Chip Market (OOC) is expected to hold a value of USD 1,020 Million by 2025 at a CAGR of 53%. Organs-on-chips (OOCs) are small plastic devices with biocompatible microfluidic chambers, which contain multiple live human cells in a 3D culture that simulate vital physiological functions of body organs. These cells are placed in an environment that artificially replicates aspects of the human body, such as morphology, movement, flow, electrical stimuli, and liquid gradients.


There has been an increase in the number of collaborative sales agreements between pharmaceutical companies and university spin-offs and the entry of new advanced models of OOCs into the market. The anticipated launch of advanced organ-specific models and human-on-chip models is expected to increase the growth rate of this market in the future further.


The small size of the market is mainly because OOCs have not yet been fully commercialized. They are still in the research and development phase and are being used by a limited number of end-users.


Market Influencer


The ability of OOC models to reduce drug development costs drastically and grants by government and non-government entities are the major factors influencing the market growth. It is expected to rise at this high CAGR due to an increase in the number of collaborative sales agreements between the pharmaceutical companies and university spin-offs and the entry of new advanced models of OOCs into the market. The anticipated launch of advanced organ-specific models and human-on-chip models is expected to further increase the growth rate of this market in the future. Grants by government and non-government entities have been the key drivers for the global OOC industry to date. The ability of OOC models to cut drug development costs drastically will be a key market driver in the future.


Moreover, improved drug screening methodologies increased R&D by major players, strategic initiatives and increasing technological advancements are also anticipated to fuel the market growth during the forecast period.


Market Drivers



  • Increasing investment by major companies in organ-on-a-chip research & development (r&d)



  • The growing demand for drug screening with organs-on-a-chips



  • Increasing focus of organ-on-chips companies on an integrated approach, OOCs for human disease models, personalized drug tests, and regulatory status of tests using MOOCs



  • Increasing government initiatives and government funding for R&D of OOCs: Major companies such as Mimetas and InSphero have been collaborating with the government agencies and universities in the US and Europe for the development of novel and effective OOCs. For instance, in 2018, InSphero received USD 10 million government funding for the R&D of said OOC models.


Market Restraints



  • Stringent government regulations for drug approvals

  • The complexity of OOC models


Segmentation


By Organ Type



  • Lung-on-Chip: It is the largest segment in the market and had a share of approximately 20% in 2018. Lung on a chip is a complex three-dimensional model of a living, breathing human lung on a microchip.



  • Heart-on-Chip: It is a device that is used to produce cardiac tissues in three-dimension models. This device is used to study cardiac drug development and cardiotoxicity testing for personalized medicine and damaged heart tissue regeneration.



  • Liver-on-Chip: This chip generates biochemical and metabolic information and shows the functioning of the liver. Fluorescent biosensor cells in the chip show changes in liver cell functions including cell death or damage to free radicals. The significant applications of liver on chips are to test general toxicity, mechanistic toxicity, and nutrient metabolism.



  • Intestine-on-Chip: These chips are used to study intestinal physiology and pathophysiology of human intestines. It is also used as a research tool for applications such as studies of metabolism, nutrition, infection, and drug pharmacokinetics, as well as personalized medicine.



  • Kidney-on-Chip: Kidney on chips constitute organ-chips, cells, and reagents. These chips are used in testing general toxicity, mechanistic toxicity, and drug transportation in kidneys. 



  • Skin-on-Chip: These chips are used in stimulating inflammation, edema, and drug-based skin disease treatments. Skin on chips is used to culture skin tissues within a microfluidic system that controls many physical and biochemical parameters of the human skin.



  • Blood-Brain Barrier-on-Chip: These chips are used in maintaining brain homeostasis, immunocytochemistry for analyzing cell morphology and protein marker expression, permeability assay, and calcium imaging for studying neuronal functioning of the brain.



  • Human-on-Chip: These are microfluidic devices that are lined with living human cells and are used for drug development, disease modeling, and personalized medicine. These chips are also used to predict human pharmacokinetic and pharmacodynamic responses of drugs on the human body.


By Application



  • Drug Discovery: The largest segment in the market, owing to a large number of pharmaceutical companies are focusing on drug testing through organ-on-chip models.



  • Toxicology Research: It is the second-largest segment in the market owing to major universities and research centers are focusing on the application of OOCs in drug toxicology testing, which is a much more advanced model compared to other drug toxicology testing methods.



  • Others: Other applications of OOCs include the food & beverage and cosmetic industries


By End-User



  • Pharmaceutical Companies: It is the largest segment owing to the rise in the number of pharmaceutical companies using OOCs for their r&d, drug toxicity, and efficacy testing.



  • Research Organizations: It is the second-largest segment in the market owing to major universities, research organizations, non-profit research centers that are focusing on the application of OOCs in drug toxicology testing. For instance, the Wyss Institute received almost USD 5.6 million in grant money from the US FDA to use its organ-on-chip technology to test humans in 2017.



  • Others: Includes small clinics and institutes and individual researchers that are working on r&d of OOCs


By Region



  • Americas: The largest regional market. Owing to the availability of a wide range of products and services offered by major players, including customized designing of new chips with specific organ arrangement and increase in toxicological testing of chemicals on the different types of organ cells.



  • Europe: It is the second-largest market and expected to grow at a steady rate during the forecast period. Establishment of major OOC providers in five countries of the European Union (EU), namely the UK, Germany, France, Italy, and Spain; government initiatives and government funding to research institutes; collaborations among companies and universities to develop innovative OOCs, and a well-developed healthcare infrastructure expected to drive the market growth.



  • Asia-Pacific: The fastest-growing regional market. Furthermore, the region has a supportive regulatory framework for the approval of OOCs in South Korea, Australia, Japan, and China. This factor, along with a high prevalence of chronic diseases, will drive the market during the forecast period.



  • Middle East & Africa: The Middle Eastern market is expected to show more growth as compared to the African market, owing to the presence of developed countries such as Saudi Arabia and Oman in the region.


Key Players



  • CN Bio Innovations Limited (UK)

  • Emulate, Inc. (US)

  • TissUse GmbH (Germany)

  • MIMETAS BV (Netherlands)

  • Hµrel Corporation

  • Nortis, Inc. (US)

  • InSphero (Switzerland)

  • TARA Biosystems, Inc. (US)

  • Axosim (US)

  • Organovo Holdings Inc. (US)

  • BioIVT (US)

  • HemoShear Therapeutics, LLC (US)



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 1,020 Million
  CAGR   53% (2019-2025)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Organ Type, Application and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   CN Bio Innovations Limited (UK), Emulate, Inc. (US), TissUse GmbH (Germany), MIMETAS BV (Netherlands), Hµrel Corporation, Nortis, Inc. (US), InSphero (Switzerland), TARA Biosystems, Inc. (US), Axosim (US), Organovo Holdings Inc. (US), BioIVT (US), HemoShear Therapeutics, LLC (US)
  Key Market Opportunities   Ability of OOC models to reduce drug development costs drastically and grants by government and non-government entities
  Key Market Drivers

  • Increasing investment by major companies in organ-on-a-chip research & development
  • The growing demand for drug screening with organs-on-a-chips


  • Frequently Asked Questions (FAQ) :


    The organ-on-a-chip market has a projected CAGR of 53% during the forecast period.

    The valuation would be USD 1,020 million by 2023.

    The restraints are stringent government rules and complex organ-on-a-chip models.

    The lung-on-chip segment has the largest market valuation.

    The drug discovery segment has the market upper hand.



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.